Dimerix Ltd (SBMJF PINK) stock market data APIs
$0.3517
0(0%)
as of September 12, 2025
Try our APIs with
free plan!
Dimerix Ltd Financial Data Overview
Price chart is built with
Anychart
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Prev. Close
0.3517
Open
0.3517
High
0.3517
Low
0.3517
52 wk Range
0.25-0.35
Market Cap
210 M
Shares Outstanding
600 M
Revenue
5 587 K
Beta
0.305
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Dimerix Ltd data using free add-ons & libraries
Get Dimerix Ltd Fundamental Data
Dimerix Ltd Fundamental data includes:
- Net Revenue: 5 587 K
- EBITDA: -31 671 536
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Dimerix Ltd News
New
ASX Penny Stocks: Botanix Pharmaceuticals And 2 Other Promising Picks
Australian shares are showing resilience as they head into Week 31 with a slight uptick, buoyed by a significant trade deal between the U.S. and European Union that promises to bring stability to glob...
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Amicus Therapeutics, Inc.; Dimerix Limited Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal Phase...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
